Jeito Capital, a global investment company, led a $105m Series C funding in Alentis Therapeutics, a clinical-stage biopharmaceutical company, with participation from Novo Holdings, RA Capital Management, Pureos Bioventures, Bpifrance and Schroders. “We are absolutely delighted with this support from our investors. There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programs. We can now aggressively develop CLDN1 biology in oncology and continue with the recruitment of our organ fibrosis trials while advancing our ADC and bi-specific antibodies,” Roberto Iacone, Alentis Therapeutics CEO.